Once-Daily Tedizolid Effective for Acute Skin InfectionsOnce-Daily Tedizolid Effective for Acute Skin Infections
Once-daily tedizolid given for 6 days is similarly effective and has similar adverse effects as linezolid given twice daily for 10 days in the treatment of acute skin and skin structure infections. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2014 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Bacteremia Caused by Linezolid-Resistant in Liverpool, United Kingdom
(Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - May 23, 2014 Category: Microbiology Authors: Edward R. Bevan, Alun Roberts, Caroline E. Corless, Timothy J. Neal Tags: Case Report Source Type: news
Treatment of Infections Due to Resistant Staphylococcus aureus
This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin–dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC w...
Source: Springer protocols feed by Microbiology - October 6, 2013 Category: Microbiology Source Type: news
Linezolid-Induced Black Hairy TongueLinezolid-Induced Black Hairy Tongue
Was this patient's black hairy tongue due to the antibiotic he was taking to treat his pneumonia? Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Trius Announces Publication Of Tedizolid ESTABLISH 1 Trial In JAMA
Key findings include: A once-daily tablet of tedizolid, given over six days, is as effective as a Zyvox (linezolid) tablet given twice a day for 10 days. This is the first published Phase 3 study under new FDA draft guidelines for acute bacterial skin and skin structure infections (ABSSSI), which call for evaluating a response to antibiotics two-to-three days after starting treatment. Response was seen in two to three days, which was a strong predictor of outcomes at the end of therapy (day 11)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 14, 2013 Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news
MRSA: Tedizolid, a New Antibiotic, Proves Effective MRSA: Tedizolid, a New Antibiotic, Proves Effective
Once-daily dosing of tedizolid phosphate for 6 days was as effective as twice-daily dosing of linezolid for 10 days. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Researchers ESTABLISH efficacy of tedizolid phosphate for skin infections
Results from the phase III ESTABLISH-1 study show that the new antibiotic tedizolid phosphate is noninferior to linezolid for the treatment of acute bacterial and skin structure infections. (Source: MedWire News - Infectious Diseases)
Source: MedWire News - Infectious Diseases - February 14, 2013 Category: Infectious Diseases Source Type: news
Researchers ESTABLISH efficacy of tedizolid phosphate for skin infections
Results from the phase III ESTABLISH-1 study show that the new antibiotic tedizolid phosphate is noninferior to linezolid for the treatment of acute bacterial and skin structure infections. (Source: MedWire News - Dermatology)
Source: MedWire News - Dermatology - February 14, 2013 Category: Dermatology Source Type: news
Shorter, Newer Antibiotic Regimen Shows Equal Effectiveness For Skin Infections
Once daily treatment with a new antibiotic called tedizolid phosphate for six days proves just as successful as the antibiotic linezolid twice a day for ten 10 days, for patients with acute bacterial skin and skin structure infections. According to the new study, published in JAMA: "Antimicrobials available for treatment of complicated skin and skin structure infections (SSSIs) are generally efficacious, but antimicrobial resistance and adverse effects limit their use... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 13, 2013 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news
RCT: Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections (ESTABLISH-1)
Source: JAMA
Area: News
Tedizolid phosphate is a novel oral, once daily oxazolidinone currently in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). The ESTABLISH-1 (Efficacy and Safety of 6-day Oral Tedizolid in Acute Bacterial Skin and Skin Structure Infections vs 10-day Oral Linezolid Therapy) study is a phase III non-inferiority study that compared tedizolid phosphate and linezolid (an oxazolidinone licensed for complicated skin and skin structure infections).
The double-blind study randomised 667 adult patients recruited from 81 study centres in North America, L...
Source: NeLM - News - February 13, 2013 Category: Drugs & Pharmacology Source Type: news
Trius Announces Publication of Tedizolid ESTABLISH 1 Trial in JAMA
SAN DIEGO, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious infections, announced today that the results from ESTABLISH 1, a Phase 3 study of tedizolid phosphate (TR-701) versus linezolid (Zyvox®) completed in 2011, have been published in (Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - February 13, 2013 Category: Pharmaceuticals Source Type: news
New Drug on Par with Standard for Skin Infections (CME/CE)
(MedPage Today) -- Acute bacterial skin infections responded equally well to treatment with linezolid (Zyvox) or a short course of the investigational agent tedizolid, results of a randomized trial showed. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 12, 2013 Category: Dermatology Source Type: news
Newer, shorter-course antibiotic shows similar effectiveness for treating skin infection
(JAMA and Archives Journals) Treatment with a newer antibiotic, tedizolid phosphate, once daily for 6 days was statistically noninferior (no worse than) in efficacy to the antibiotic linezolid twice daily for 10 days for both early (at day 2 to 3) and sustained (at day 11) clinical responses in patients with acute bacterial skin and skin structure infections, according to a study appearing in the Feb. 13 issue of JAMA. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 12, 2013 Category: Infectious Diseases Source Type: news
SMC accepts ceftaroline fosamil (ZinforoT) for restricted use for adults with complicated skin and soft tissue infections
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted ceftaroline fosamil (ZinforoT) for restricted use within NHS Scotland in adults with complicated skin and soft tissue infections.
The SMC restriction applies to use in patients with known or suspected meticillin resistant Staphylococcus aureus (MRSA) infection in the following settings:
. For Gram-positive only infections where vancomycin IV is inappropriate/has not been tolerated or treatment modification is required; and daptomycin IV or linezolid IV is normally...
Source: NeLM - Drug Specific Reviews - January 15, 2013 Category: Drugs & Pharmacology Source Type: news
